Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.46% -0.04% 3.045B 228507.1
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
1.00% 23.00% 195.54M Upgrade

Basic Info

Investment Strategy
The investment seeks to track the investment results of the Morningstar® Exponential Technologies IndexSM composed of stocks of developed and emerging market companies that create or use exponential technologies. The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The underlying index is a subset of the Morningstar Global Markets Index (the “Parent index”).
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Miscellaneous Sector
Category Index Morningstar US Market TR USD
Prospectus Objective Specialty - Technology
Fund Owner Firm Name iShares
Prospectus Benchmark Index
Morningstar Exponential Tech NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Greg Savage 7.21 yrs
Jennifer Hsui 7.21 yrs
Amy Whitelaw 3.50 yrs
Paul Whitehead 0.41 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 24
195.54M
-307.75M Category Low
708.87M Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of May 31, 2022

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of June 24, 2022. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
9.42%
33.71%
-4.88%
30.73%
35.09%
16.43%
-23.96%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
21.82%
-18.24%
--
--
58.01%
-28.35%
31.79%
51.91%
8.65%
-39.93%
-6.21%
-2.69%
32.33%
-12.37%
42.65%
184.0%
-3.21%
-18.34%
2.34%
12.42%
30.52%
-12.48%
36.45%
51.02%
2.51%
-15.94%
-5.51%
22.69%
27.43%
-22.69%
42.83%
48.82%
27.64%
-21.20%
As of June 24, 2022.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (6-27-22) 1.00%
30-Day SEC Yield (4-30-18) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 20.42
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of June 23, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of June 23, 2022

Asset Allocation

As of June 23, 2022.
Type % Net % Long % Short
Cash 0.21% Upgrade Upgrade
Stock 99.79% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Sociedad Quimica Y Minera De Chile SA Pfd Registered Shs Series -B-
1.03% -- --
Jazz Pharmaceuticals PLC 0.97% 156.68 2.08%
Bristol-Myers Squibb Co 0.94% 80.00 1.32%
CF Industries Holdings Inc 0.92% 86.81 4.19%
Mandiant Inc 0.89% 21.86 -0.36%
Merck & Co Inc 0.88% 94.39 1.35%
Shanghai Junshi Biosciences Co Ltd Class A
0.88% -- --
Exelixis Inc 0.87% 22.20 -0.09%
Eli Lilly and Co 0.87% 327.18 0.48%
Ionis Pharmaceuticals Inc 0.84% 39.34 0.23%

Basic Info

Investment Strategy
The investment seeks to track the investment results of the Morningstar® Exponential Technologies IndexSM composed of stocks of developed and emerging market companies that create or use exponential technologies. The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The underlying index is a subset of the Morningstar Global Markets Index (the “Parent index”).
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Miscellaneous Sector
Category Index Morningstar US Market TR USD
Prospectus Objective Specialty - Technology
Fund Owner Firm Name iShares
Prospectus Benchmark Index
Morningstar Exponential Tech NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Greg Savage 7.21 yrs
Jennifer Hsui 7.21 yrs
Amy Whitelaw 3.50 yrs
Paul Whitehead 0.41 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (6-27-22) 1.00%
30-Day SEC Yield (4-30-18) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 20.42
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of June 23, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of June 23, 2022

Fund Details

Key Dates
Inception Date 3/19/2015
Last Annual Report Date 7/31/2021
Last Prospectus Date 12/20/2021
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund Yes

Top Portfolio Holders

0 of 0